Jagsonpal Pharmaceuticals Limited Stock Fundamentals
| JAGSNPHARM | 213.70 17.70 7.65% |
Jagsonpal Pharmaceuticals Limited fundamentals help investors to digest information that contributes to Jagsonpal Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Jagsonpal Stock. The fundamental analysis module provides a way to measure Jagsonpal Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jagsonpal Pharmaceuticals stock.
As of now, Jagsonpal Pharmaceuticals' EBITDA is increasing as compared to previous years. The Jagsonpal Pharmaceuticals' current Total Operating Expenses is estimated to increase to about 809.7 M, while Depreciation And Amortization is projected to decrease to under 14.6 M. Jagsonpal | Select Account or Indicator |
Jagsonpal Pharmaceuticals Limited Company Return On Asset Analysis
Jagsonpal Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Jagsonpal Pharmaceuticals Return On Asset | 0.0605 |
Most of Jagsonpal Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jagsonpal Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Jagsonpal Total Assets
Total Assets |
|
Based on the latest financial disclosure, Jagsonpal Pharmaceuticals Limited has a Return On Asset of 0.0605. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on asset for all India stocks is notably lower than that of the firm.
Jagsonpal Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Jagsonpal Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Jagsonpal Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jagsonpal Pharmaceuticals competition to find correlations between indicators driving Jagsonpal Pharmaceuticals's intrinsic value. More Info.Jagsonpal Pharmaceuticals Limited is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.46 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Jagsonpal Pharmaceuticals Limited is roughly 2.19 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Jagsonpal Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jagsonpal Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Jagsonpal Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jagsonpal Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jagsonpal Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jagsonpal Pharmaceuticals by comparing valuation metrics of similar companies.Jagsonpal Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Jagsonpal Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0605 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 13.52 B | ||||
| Shares Outstanding | 66.36 M | ||||
| Shares Owned By Insiders | 73.66 % | ||||
| Shares Owned By Institutions | 1.47 % | ||||
| Price To Book | 7.20 X | ||||
| Price To Sales | 6.26 X | ||||
| Revenue | 2.09 B | ||||
| Gross Profit | 1.34 B | ||||
| EBITDA | 323.46 M | ||||
| Net Income | 224.63 M | ||||
| Cash And Equivalents | 110.53 M | ||||
| Total Debt | 89.41 M | ||||
| Book Value Per Share | 74.42 X | ||||
| Cash Flow From Operations | 351.66 M | ||||
| Earnings Per Share | 3.59 X | ||||
| Number Of Employees | 1.02 K | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 14.2 B | ||||
| Total Asset | 2.17 B | ||||
| Retained Earnings | 1.04 B | ||||
| Working Capital | 1.8 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 2.17 B |
About Jagsonpal Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jagsonpal Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jagsonpal Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jagsonpal Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 11.6 M | 11.1 M | |
| Total Revenue | 2.4 B | 1.8 B | |
| Cost Of Revenue | 1.6 B | 876.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Other Information on Investing in Jagsonpal Stock
Jagsonpal Pharmaceuticals financial ratios help investors to determine whether Jagsonpal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jagsonpal with respect to the benefits of owning Jagsonpal Pharmaceuticals security.